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a b s t r a c t
Background: The purpose of this study was to investigate the inﬂuence of tranexamic acid (TXA) on
functional outcomes in the immediate postoperative period after total knee arthroplasty (TKA). We
hypothesized that the known beneﬁts of TXAwould confer measurable clinical improvements in physical
therapy (PT) performance, decrease pain, and decrease hospital length of stay (LOS).
Methods: We retrospectively analyzed 560 TKA patients, including 280 consecutive patients whose
surgery was performed before the initiation of a standardized TXA protocol and the ﬁrst 280 patients
who received TXA after protocol initiation. Outcome measurements included postoperative changes in
hemoglobin and hematocrit, LOS, pain scores, destination of discharge, and steps ambulated with PT over
5 sessions.
Results: TXA administration resulted in less overall drops in hemoglobin (P < .001) and hematocrit levels
(P < .001). Moreover, patients administered TXA ambulated more than their counterparts during every
PT session, which was statistically signiﬁcant during the second (P ¼ .010), third (P ¼ .011), and fourth
(P ¼ .024) sessions. On average, the TXA cohort ambulated 20% more per PT session than patients who
did not receive TXA (P < .001). TXA administration did not inﬂuence pain levels during PT, hospital LOS,
or discharge destination in this investigation.
Conclusions: It is well known that TXA reduces postoperative anemia, but this study also demonstrates
that it confers early perioperative functional beneﬁts for TKA patients. Potential mechanisms for this
beneﬁt include reduced rates of postoperative anemia and reduced rates of hemarthroses.
© 2017 The Authors. Published by Elsevier Inc. on behalf of The American Association of Hip and Knee
Surgeons. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
Introduction
Over the last decade, the perioperative use of tranexamic acid
(TXA) during total knee arthroplasty (TKA) has been shown to
confer signiﬁcant beneﬁts. Multiple randomized controlled trials
have clearly demonstrated clinically signiﬁcant reduction in peri-
operative bleeding, perioperative anemia, and transfusion
requirements with both intravenous (IV) and topical TXA admin-
istration [1-5]. Reduction in perioperative bleeding is reported
between 110 and 690 mL, with a mean difference of 245 mL [1].
Reduction in transfusion rates across 14 studies showed a mean
relative risk reduction of 2.56 (P < .001) [1].
Achieving faster and safer recovery in the perioperative period is
of increasing importance in the arthroplasty ﬁeld. Accelerated re-
covery can lead to decreased costs through increased patient in-
dependence, a shorter hospital stay, and decreased need for
posthospital rehabilitation facilities. The considerable reductions
seen in perioperative blood loss related outcomes with the use of
TXA may translate to improved functional beneﬁts in this period.
Improving postoperative anemia and decreasing intra-articular
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hematoma formation may lead to decrease pain and measurable
clinical improvement in functional outcomes in the acute post-
operative period.
The primary purpose of this study was to investigate the inﬂu-
ence of TXA on functional improvement in the immediate post-
operative period after TKA. We hypothesized that TXA would
confer measurable clinical improvement in physical therapy (PT)
performance by improving postoperative anemia and decreasing
pain associated with intra-articular hematomas, which would
result in short hospital length of stay (LOS) and a decreased rate of
patient discharges to a rehabilitation facility.
Material and methods
Experimental protocol
After institutional review board's approval, we retrospectively
analyzed patients receiving a TKA by the senior surgeon at one
institution between October 1, 2010 and November 1, 2014. Our
institution began implementing the use of TXA protocol for TKA
patients in May 2013. Patients undergoing bilateral TKA, or who
had an operative diagnosis that included infection or trauma, and
patients who suffered from blood-related disorders that may have
affected their need for transfusion were excluded.
In this case-control study, the patients were divided into
2 groups. The control group consisted of 280 consecutive patients
who underwent surgery between October 2010 and May 2013, and
did not receive TXA, whereas the TXA cohort comprised the sub-
sequent 280 patients, who underwent TKA between May 2013 and
November 2014 after initiation of the TXA protocol. These patients
received 1 gram of IV TXA immediately before incision and an
additional 1 gram of IV TXA before wound closure. There were 22
patients who did not have complete records and were eliminated
from the analysis leaving 264 patients in the TXA cohort and 274
patients in the control cohort.
Data collected included demographics, preoperative functional
status based on American Society of Anesthesiologists (ASA)
physical status classiﬁcation system, preoperative hemoglobin
(HGB) and hematocrit (HCT) levels. Outcome measures collected
included postoperative changes in HGB and HCT levels, transfusion
events, LOS, visual analogue scale (VAS) pain scores, distance
ambulated with PT over 5 sessions or until discharge, and desti-
nation of discharge (home or rehabilitation center).
Statistical analysis
Demographics, preoperative functional status, and preoperative
HGB and HCT levels were compared between the 2 groups to
identify any baseline differences between the 2 cohorts. Preoper-
ative differences and postoperative outcomemeasures between the
2 groups were compared using chi-square analysis or Fischer exact
test for categorical variables, and Student t test for continuous
variables. Multivariate analysis using multiple logistic regression
comparing outcome measures for each group were performed
while controlling for gender, BMI, age, preoperative HCT and HGB
levels, and preoperative functional status. A P value <.05 was
considered signiﬁcant for all analyses.
Results
Patient demographics and preoperative characteristics
The patient cohorts had similar demographics and preoperative
variables including age, ASA grade, body mass index (BMI), and
preoperative HGB and HCT levels (Table 1). However, there were a
signiﬁcantly higher proportion of female patients in the TXA cohort
(76.1%) compared with the control cohort (66.1%) (P ¼ .01).
Outcomes for TXA vs control cohort
TXA administration resulted in reduced postoperative decreases
in HGB (1.9 vs 2.6) and HCT (5.8 vs 7.8) (P < .001) (Table 2). There
was also a trend toward decreased transfusion rates in TKA patients
receiving TXA, although this was not signiﬁcant (1.1% vs 3.7%,
P ¼ .089).
Patients administered TXA ambulated more than their coun-
terparts during every PT session (Fig. 1, Table 3), which was sta-
tistically signiﬁcant during the second (P ¼ .010), third (P ¼ .011),
and fourth (P ¼ .024) sessions. On average, the TXA cohort ambu-
lated 20% more per PT session than patients who did not receive
TXA, 65.8 feet vs 54.9 feet (P < .001). TXA did not signiﬁcantly in-
ﬂuence VAS pain scores taken before and after PT sessions, or mean
VAS score through hospital stay (Table 3). There was no signiﬁcant
difference in knee range of motion (ROM) between the 2 cohorts at
3 months (control 115.0, TXA 114.1, P ¼ .54) and 1 year follow-up
(control 117.1, TXA 118.6, P ¼ .36).
Clinical pathways between the 2 cohorts remained the same,
with regards to similar multimodal pain management protocols
(including a preoperative femoral nerve block), anesthesia pro-
tocols, rehabilitation protocols, and mobilization protocols. The
average hospital LOS for controls (3.8 days) and TXA patients
(3.6 days) was not signiﬁcantly different (Table 2). There was no
difference in the distribution of patients going home vs rehabili-
tation at the time of discharge, with about 36% of patients able to go
home after TKA regardless of TXA administration.
Multivariate analysis
When taking into account age, BMI, gender, preoperative func-
tional ASA status, and preoperative HCT and HGB levels,
Table 1
Patient demographics and preoperative characteristics.
Variable Total (n ¼ 538) Control cohort (n ¼ 274) TXA cohort (n ¼ 264) P value
Age, y 69.1 (19-94, 10.4) 69.5 (35-92, 10.0) 68.7 (19-94, 10.9) .202
Gender
Male 155 (29) 92 (34) 63 (24) .010a
Female 383 (71) 182 (66) 201 (76)
BMI, kg/m2 31.0 (18.1-92.2, 6.7) 31.1 (18.1-58.2, 6.0) 31.0 (18.2-54.6, 7.5) .368
Preoperative HGB, g/dL 13.1 (7.6-17.3, 1.4) 13.1 (7.6-17.3, 1.4) 13.1 (9-16.9, 1.4) .837
Preoperative HCT, % 39.9 (23.4-51.7, 3.7) 39.7 (23.4-51.7, 3.7) 40.1 (28.5-49.9, 3.7) .530
ASA status 2.3 (1-4, 0.5) 2.4 (1-4, 0.5) 2.3 (1-4, 0.5) .283
PNB, % 528 (94) 260 (93) 268 (96) .152
PNB, peripheral nerve block.
For continuous variables mean (range, standard deviation); for categorical variables N (%).
a Signiﬁcant for P value <.05.
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multivariate logistic regression analysis conﬁrmed an association
between TXA use and signiﬁcantly increased ambulation with PT
during the second, third, and fourth PT sessions (Table 4). In addi-




Similar to numerous previously published level 1 studies, we
found that TXA is efﬁcacious in reducing postoperative anemia. In
this study, we also found that the administration of IV TXA
conferred additional functional beneﬁts for the TKA patient as pa-
tients who received IV TXA were more active than the non-TXA
patients, with statistically improved ambulation within the days
immediately after surgery. No inﬂuence was found for decreased
pain scores, earlier hospital discharge, or discharge location.
Nevertheless, as improved mobility in the postoperative period
may help to minimize complications [6-9], this study further sup-
ports TXA as a useful adjunct for lower extremity arthroplasty.
Comparison to the literature
The role of TXA in improving patient function has not been well
studied. In a similarly designed retrospective study, Serrano Mateo
et al. [10] examined 388 TKAs, for which roughly half received
topical TXA, and examined differences in functional Knee Society
Score and knee-speciﬁc Knee Society score (KKSS) between the
2 groups at 6 weeks and 4 months. They reported signiﬁcantly
greater functional Knee Society Score for the TXA group at 6 weeks,
although this difference disappeared at 4 months. In addition, two
other studies reported patient reported outcomes at 3 months
follow-up, but they reported no difference between TXA and con-
trol groups [2,4]. Lastly, Wang et al. and Georgiadis et al. [11,12]
examined ROM at 3 weeks or 6 weeks, and only Wang et al.
found signiﬁcantly greater ROM in the TXA group at 6 weeks.
To our knowledge, our study is the ﬁrst to examine functional
outcomes in the immediate postoperative period. Increased early
activity after TKA is associated with reduced complications, which
may be an additional potential beneﬁt of TXA [6-9]. Although we did
not report signiﬁcant differences in ROMat 1month follow-up, other
studies did see functional improvements during this period. Serrano
Mateo et al. and Wang et al. studies [10,11] report improved ROM
and functional scores during the ﬁrst 1-2 postoperative months.
Regarding functional outcomes, postoperative anemia can take
weeks tomonths to correct, and therefore, the functional beneﬁt can
possibly extend for this period. Although ROM was not signiﬁcantly
different between groups, this study limited its measurement of
other long-term functional outcome measures. Diminished local
bleeding (hidden blood loss) and swelling in the postoperative
period can lead to improved comfort and knee function. In a study by
Ishida et al. [13], they observed a signiﬁcantly decreased thigh,
suprapatellar, and calf girth in the TXA group compared with the
control group at 1 week. Karaaslan et al. [14] observed decreased
rates of intra-articular hemarthrosis in knee surgery after the
administration of TXA. Reduced rates of hemarthroses in the knee
Table 2








12.0 (7.5-17, 1.4) 12.2 (7.1-15.4, 1.4) .066
POD1 HGB, g/dL 10.5 (6.2-15.4, 1.3) 11.2 (8.5-14.8, 1.3) <.001a
Change in HGB,
g/dL
2.6 (7.1 to 0.1, 0.98) 1.9 (1 to 4.5, 1.0) <.001a
Postoperative HCT 36.7 (23.9-50.7, 3.9) 37.3 (7.1-15.4, 1.4) .047a
POD1 HCT 32.0 (18.6-46.6, 3.9) 34.2 (20.1-47.3, 3.7) <.001a
Change in HCT 7.8 (21.8 to 1.1, 3.1) 5.8 (14.9 to 2.8, 2.9) <.001a
Postoperative
transfusion
10 (3.7) 3 (1.1) .089
Length of stay, d 3.8 (2.1-33, 2.3) 3.6 (1.3-8.4, 1.1) .231
Discharge location
Home 100 (36) 95 (36) .569
Rehabilitation
facility
174 (64) 169 (64)
POD, postoperative day.
For continuous variables mean (range, standard deviation); for categorical variables
N (%); aSigniﬁcant for P value <.05.
Figure 1. Comparison of number of steps ambulated during the ﬁrst 5 physical therapy
sessions between patients who received TXA and who did not receive TXA. *P < .05.
Table 3







First session 30 (0-600, 50) 33.8 (0-600, 49) .38
Second session 38 (0-400, 51) 51 (0-400, 67) .010a
Third session 58 (0-400, 63) 74 (0-600, 82) .011a
Fourth session 76 (0-550, 76) 80 (0-600, 96) .024a
Fifth session 92 (0-600, 90) 98 (0-600, 93) .532
Total PT ambulation 262 (2-1760, 247) 310 (4-2210, 299) .041a
VAS pain scores pre-PT
First session 3.0 (0-10, 2.8) 3.4 (0-10, 2.9) .07
Second session 3.0 (0-10, 2.8) 3.3 (0-10, 2.9) .19
Third session 3.4 (0-10, 2.8) 3.3 (0-10, 2.7) .92
Fourth session 3.1 (0-10, 2.9) 2.7 (0-10, 2.6) .13
Fifth session 2.6 (0-10, 2.6) 2.3 (0-10, 2.4) .28
VAS pain scores post-PT
First session 3.4 (0-10, 2.9) 3.4 (0-10, 2.9) .93
Second session 3.3 (0-10, 2.9) 3.3 (0-10, 3.0) .92
Third session 3.8 (0-10, 2.8) 3.3 (0-10, 2.8) .070
Fourth session 3.3 (0-10, 2.9) 2.8 (0-10, 2.7) .070
Fifth session 3.1 (0-10, 2.7) 2.6 (0-10, 2.5) .067
Mean (range, standard deviation); aSigniﬁcant for P value <.05.
Table 4
Results of multivariate logistic regression analysis for physical therapy ambulation.
Physical therapy ambulation Odds ratio 95% conﬁdence interval P value
First session 1.002 0.998-1.006 .381
Second session 1.004 1.001-1.008 .007a
Third session 1.003 1.001-1.006 .009a
Fourth session 1.003 1.000-1.005 .024a
Fifth session 1.001 0.999-1.003 .377
Total PT 1.001 1.000-1.001 .034a
a Signiﬁcant for P value <.05.
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after the administration of TXA may be the potential mechanism for
improved perioperative functional outcomes.
In this study, no signiﬁcant differences were observed for pain
scores, time to hospital discharge, and rates of discharge to a
rehabilitation facility or home between the 2 groups. One possi-
bility for similar VAS scores was efﬁcacy of the multimodal pain
regimen. For example, most patients received peripheral nerve
blocks, which likely controlled knee pain in the ﬁrst 24-48 hours,
limiting the pain effect of an increased hemarthrosis, while still
potentially effecting willingness to ambulate. The current literature
varies on whether TXA administration reduces LOS, with both
randomized control trials and retrospective studies showing both
outcomes [2,3,12,15-18]. Like disposition status, this outcome is
multifactorial in nature, and can vary based on personal and
institutional preferences. Of note, none of the studies that report
decreased LOS were performed in the United States [2,16-18].
Longer average LOSs in countries outside of the United States may
account for this difference. Furthermore, patient disposition is not
always dependent on functional status, and it is often affected by
patient's preference.
Study limitations
The primary limitation of this study is that it is a retrospective
study of prospectively collected data. We attempted to identify
potential selection bias between the 2 cohorts that may affect
functional outcomes (Table 1). There were no differences for any of
the variables, except for percentage female. Of note, gender did not
inﬂuence functional outcomes in our subanalysis, and the effect of
TXA on ambulation remained after a logistic regression analysis
which included gender as a variable. There were no major changes
regarding drain usage, pain management, or implants used during
this period. However, there could be changes in surgical manage-
ment, as well as hospital policy, that the authors did not identify
that may affect these ﬁndings, and this is a limitation of this study.
Secondly, at our institution, we used IV TXA for our TKA patients.
The optimal administration of TXA is controversial, with some
studies showing no difference between topical and IV administra-
tion [19,20], some favoring topical [21], and some favoring IV [22].
Many studies examining functional outcomes used topical TXA, and
the difference, if any, between IV and topical on functional out-
comes is yet to be determined.
Furthermore, we did not speciﬁcally subanalyze groups based
on their mode of venous thromboprophylaxis, as those patients
using a stronger agent may have affected the groupings. We eval-
uated the cohort across all modalities of prophylaxis to evaluate the
effect irrespective of blood thinner. The main agents were aspirin
(325 mg bid), rivaroxaban (10 mg qd), and warfarin (international
normalized ratio [INR] goal 2.0-2.5).
Conclusions
In summary, TXA is efﬁcacious in reducing postoperative ane-
mia, which conferred functional beneﬁts for arthroplasty patients
in being able to perform better with PT in the immediate post-
operative period after TKA. Improved mobility in the perioperative
period, which can help minimize complications, is one more
indication for the use of TXA in TKA.
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